ADR Therapeutics Launches Joint Research with Northern Farm on 'Neocella' to Improve Thoroughbred Breeding Disorders
ADR Therapeutics has announced a joint research agreement with Northern Farm to study the application of 'Neocella,' a next-generation extracellular particle product, for treating breeding disorders (PMIE) in thoroughbreds. The project aims to accelerate development by combining field case studies and veterinary analysis during the 2026 breeding season with ongoing basic research.
📋 Article Processing Timeline
- 📰 Published: May 20, 2026 at 00:44
- 🔍 Collected: May 19, 2026 at 16:01
- 🤖 AI Analyzed: May 20, 2026 at 08:12 (16h 10m after Collected)
ADR Therapeutics, a subsidiary of ADR120S Inc. (Tokyo Stock Exchange Standard: 3750; President: Masamichi Hashimoto), announced today that it has entered into a joint research agreement with Northern Farm, a leader in thoroughbred production and training in Japan, to conduct application research on 'Neocella,' a next-generation extracellular particle product, in the field of thoroughbred breeding.
Background of the Joint Research: Addressing 'Breeding Disorders' in the Global Horse Racing Industry
In the realm of thoroughbred breeding, intrauterine inflammation, fluid accumulation, and chronic inflammation are major factors causing 'decreased conception rates.' Among these, 'Persistent Mating-Induced Endometritis (PMIE)' is recognized globally as a critically severe breeding disorder, creating an urgent need for effective solutions.
In this joint research, we will verify the potential of 'Neocella,' developed by our company, to improve the intrauterine environment for inflammatory conditions including PMIE.
Key Activities of the Joint Research
Focusing on field case accumulation and observation during the 2026 breeding season, we will conduct veterinary analysis and research evaluation on the following:
- Observational research on improving the intrauterine environment in breeding mares
- Examination of potential applications for inflammatory conditions such as PMIE
- Evaluation of the utility of cell-derived components in the breeding domain
- Accumulation of case data and veterinary analysis
- Collection of medical evidence to facilitate overseas licensing of Neocella
Accelerating Development through a 'Two-Track' Approach
As announced on May 14, 2026, ADR Therapeutics has entered into a joint research agreement with Tokyo Medical University, a world-renowned authority in exosome research, to conduct basic research on Neocella, including biological function evaluation, mechanism of action analysis, and inflammatory control functions.
This project with Northern Farm is positioned as a key initiative to promptly evaluate the 'potential for real-world application' in the thoroughbred breeding domain, parallel to the 'basic research' being conducted with Tokyo Medical University.
Future Outlook
Our group will strongly promote both scientific analysis with Tokyo Medical University and practical research with Northern Farm. Detailed data and analysis results obtained from this joint research will be considered for public disclosure after the end of the 2026 breeding season, following case organization and continuous evaluation.
The impact of this contract on our business results is currently considered to be minor. We will promptly announce any matters that require disclosure in the future.
Background of the Joint Research: Addressing 'Breeding Disorders' in the Global Horse Racing Industry
In the realm of thoroughbred breeding, intrauterine inflammation, fluid accumulation, and chronic inflammation are major factors causing 'decreased conception rates.' Among these, 'Persistent Mating-Induced Endometritis (PMIE)' is recognized globally as a critically severe breeding disorder, creating an urgent need for effective solutions.
In this joint research, we will verify the potential of 'Neocella,' developed by our company, to improve the intrauterine environment for inflammatory conditions including PMIE.
Key Activities of the Joint Research
Focusing on field case accumulation and observation during the 2026 breeding season, we will conduct veterinary analysis and research evaluation on the following:
- Observational research on improving the intrauterine environment in breeding mares
- Examination of potential applications for inflammatory conditions such as PMIE
- Evaluation of the utility of cell-derived components in the breeding domain
- Accumulation of case data and veterinary analysis
- Collection of medical evidence to facilitate overseas licensing of Neocella
Accelerating Development through a 'Two-Track' Approach
As announced on May 14, 2026, ADR Therapeutics has entered into a joint research agreement with Tokyo Medical University, a world-renowned authority in exosome research, to conduct basic research on Neocella, including biological function evaluation, mechanism of action analysis, and inflammatory control functions.
This project with Northern Farm is positioned as a key initiative to promptly evaluate the 'potential for real-world application' in the thoroughbred breeding domain, parallel to the 'basic research' being conducted with Tokyo Medical University.
Future Outlook
Our group will strongly promote both scientific analysis with Tokyo Medical University and practical research with Northern Farm. Detailed data and analysis results obtained from this joint research will be considered for public disclosure after the end of the 2026 breeding season, following case organization and continuous evaluation.
The impact of this contract on our business results is currently considered to be minor. We will promptly announce any matters that require disclosure in the future.
FAQ
Why is this research important?
It aims to establish a new treatment using extracellular particles for Persistent Mating-Induced Endometritis (PMIE), a global challenge in thoroughbred production.
What is Neocella used for?
It is being tested for improving the intrauterine environment and treating inflammatory conditions (such as PMIE) in breeding mares.
What is the structure of the research?
It proceeds on two tracks: basic research with Tokyo Medical University and field testing at Northern Farm.